Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 7.363 billion yuan for FY2025, representing a year-on-year growth of 11.9%. The adjusted net profit was approximately 2.049 billion yuan, impacted by a non-cash impairment charge of 1.706 billion yuan related to goodwill and intangible assets [2][3] - The decline in gross margin to 53.3% was attributed to increased educational investment, while the net profit margin showed a smaller decline due to reduced administrative expenses and financing costs [4] - Capital expenditures significantly decreased by 45.2% to 2.66 billion yuan in FY2025, with expectations for continued decline as new educational facilities are completed [4][5] Summary by Sections Financial Performance - FY2025 revenue reached 7.363 billion yuan, with a year-on-year increase of 11.9%. The adjusted EBITDA was 4.169 billion yuan, and the net profit was 506 million yuan, reflecting a 132.3% increase in attributable net profit [2][3] - The number of full-time students increased by 5% to 282,000, with higher education students growing by 9% to 243,000, while secondary vocational education students decreased by 15.2% to 39,000 [3] Profitability Metrics - The gross margin decreased by 2.1 percentage points to 53.3%, while the net profit margin was 6.9%, showing a slight decline of 0.8 percentage points [4] - The company’s financial metrics indicate a net profit margin improvement due to lower administrative expenses and financing costs [4] Capital Expenditure and Future Outlook - Capital expenditures for FY2025 were 2.66 billion yuan, down 45.2% from the previous year, with expectations for further reductions as construction projects are completed [4][5] - Adjusted revenue forecasts for FY2026 and FY2027 have been revised down to 7.743 billion yuan and 8.139 billion yuan, respectively, with corresponding adjusted net profit estimates of 2.172 billion yuan and 2.337 billion yuan [6]

Investment Rating - The report suggests a cautious subscription for Tianyu Semiconductor (2658.HK) [4] Core Insights - The company focuses on the manufacturing of self-produced silicon carbide (SiC) wafers, which are essential raw materials for power semiconductor devices. Compared to traditional semiconductor materials like silicon, SiC offers significant performance advantages, making it suitable for high-voltage, high-temperature, and high-frequency environments [2] - According to Frost & Sullivan, the company ranks as the third-largest SiC wafer manufacturer in China, with a market share of 6.7% by revenue and 7.8% by volume as of 2024 [2] - The global market for SiC power semiconductor devices is projected to grow significantly, from USD 600 million in 2020 to USD 3.2 billion in 2024, representing a compound annual growth rate (CAGR) of 49.8%. The market is expected to reach USD 15.8 billion by 2029, with a CAGR of 40.5% from 2025 to 2029 [3] Summary by Sections IPO Details - The IPO price is set at HKD 58 per share, with a total fundraising amount of HKD 1.6711 billion. The total number of shares offered is approximately 3,007,050 shares, with 90% allocated for international placement and 10% for public offering [1] Financial Performance - The company's revenues for 2022, 2023, and 2024 were RMB 436.86 million, RMB 1,171.21 million, and RMB 519.62 million, respectively. The net profits for the same years were RMB 6.95 million, RMB 101.44 million, and RMB -492.45 million, indicating a decline in 2024 primarily due to reduced market prices and overseas sales of SiC wafers [3] Market Position - The company has an annual production capacity of approximately 420,000 6-inch and 8-inch wafers, making it one of the largest producers in China for these sizes [2] - The presence of Huawei's Hubble Technology as an investor is expected to provide significant growth opportunities for the company in the medium to long term [4]

Investment Rating - The report suggests a cautious subscription for the company "Encounter Noodle" (2408.HK) [1][4] Core Insights - Encounter Noodle is the largest operator of Sichuan-Chongqing style noodle restaurants in China, with a network of 451 restaurants in 22 cities in mainland China and 14 in Hong Kong [2] - The Chinese noodle restaurant market is expected to grow at a CAGR of 11.0% from 2025 to 2029, outpacing the average growth of the Chinese fast food market at 9.0% [2] - The company has shown significant revenue growth, with projected revenues of 8.01 billion, 11.54 billion, and 7.03 billion CNY for the fiscal years 2023, 2024, and the first half of 2025, respectively, representing year-on-year growth rates of 91.47%, 44.21%, and 33.77% [3] - The company's net profit for the same periods is projected to be 0.46 billion, 0.61 billion, and 0.42 billion CNY, with year-on-year growth rates of 227.63%, 32.2%, and 95.77% [3] - The current median IPO price of 6.34 HKD corresponds to a PE ratio of approximately 67 for 2024, and assuming similar growth rates, a PE ratio of about 34 for 2025, indicating a high valuation [4] Summary by Sections IPO Details - The IPO price range is set between 5.64 and 7.04 HKD, with a median price of 6.34 HKD [1] - The total fundraising amount is estimated at 5.516 billion HKD [1] - The total number of shares available for subscription is 9,736,450, with 90% allocated for international placement and 10% for public offering [1] Company Performance - The company has expanded its store count significantly, with 252, 360, and 417 stores for the fiscal years 2023, 2024, and the first half of 2025, respectively [3] - Same-store sales have shown fluctuations, with a decline in 2024 attributed to price reductions, although daily orders have increased [3] - The direct restaurant profit margins have improved, reaching 12.5%, 13.3%, and 15.1% for the respective periods, benefiting from cost control and operational efficiency [3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 248.49 HKD / 226.29 CNY [3][5]. Core Insights - The company's Blizzard games are gradually resuming operations, and the evergreen game "Yan Yun Shi Liu Sheng" is performing excellently both domestically and internationally. The anticipated launch of "Forgotten Sea" in 2026 is expected to drive growth [3]. - The adjusted profit forecasts for the company from 2025 to 2027 are 362 billion, 398 billion, and 450 billion CNY respectively, reflecting slight adjustments based on game performance and Q3 financial results [3]. Financial Performance Summary - **Revenue Forecasts**: The company expects revenues of 103,468 million CNY in 2023, growing to 138,188 million CNY by 2027, with a CAGR of approximately 12.37% from 2025 to 2027 [4]. - **Net Profit**: The net profit attributable to the parent company is projected to increase from 29,417 million CNY in 2023 to 44,999 million CNY in 2027, with a notable growth rate of 21.98% in 2025 [4]. - **Earnings Per Share (EPS)**: EPS is expected to rise from 9.29 CNY in 2023 to 14.20 CNY in 2027 [4]. - **Profit Margins**: The gross margin is projected to improve from 60.95% in 2023 to 66.19% in 2027, while the net margin is expected to stabilize around 32% [4]. Market Performance - The company's stock price as of November 20, 2025, was 212.6 HKD, with a 52-week high of 248 HKD and a low of 125.99 HKD [5]. - The company's market capitalization is approximately 673,508 million HKD [5]. Game Performance Insights - The total revenue from games and related value-added services in Q3 2025 was 233 billion CNY, reflecting a year-on-year growth of 12% [10]. - The game "Dream Journey" continues to see high activity levels, and "Yan Yun Shi Liu Sheng" is expected to perform well in overseas markets in Q4 [10].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company is experiencing a recovery in Blizzard games, with the evergreen game "Yanyun Sixteen Sounds" performing well both domestically and internationally. The anticipated launch of "Forgotten Sea" in 2026 is expected to drive growth. The adjusted net profit forecasts for 2025-2027 are 362 billion, 398 billion, and 450 billion CNY respectively, reflecting slight adjustments based on game performance and Q3 financial results. The target price is set at 248.49 HKD / 226.29 CNY [3][5] Financial Performance Summary - **Revenue Forecasts**: The company’s revenue is projected to grow from 103,468 million CNY in 2023 to 138,188 million CNY in 2027, with year-on-year growth rates of 7.23%, 1.77%, 7.77%, 8.37%, and 12.37% respectively [4] - **Operating Profit**: Operating profit is expected to increase from 27,709 million CNY in 2023 to 45,775 million CNY in 2027, with significant growth in 2025 at 22.22% [4] - **Net Profit**: The net profit attributable to the parent company is forecasted to rise from 29,417 million CNY in 2023 to 44,999 million CNY in 2027, with a notable growth of 21.98% in 2025 [4] - **Earnings Per Share (EPS)**: EPS is projected to grow from 9.29 CNY in 2023 to 14.20 CNY in 2027 [4] - **Profitability Ratios**: The gross margin is expected to improve from 60.95% in 2023 to 66.19% in 2027, while the net margin is projected to increase from 28.43% to 32.56% over the same period [4] Market Performance - The company's stock price as of November 20, 2025, was 212.6 HKD, with a 52-week high of 248 HKD and a low of 125.99 HKD [5]

Investment Rating - The report maintains an "Outperform" rating for Super Hi International Holding [2][15]. Core Views - The company has shown improvement in table turnover rates and is steadily advancing its multi-brand strategy. The revenue for 3Q25 reached USD 210 million, a year-on-year increase of 7.8%, while net profit attributable to shareholders decreased by 90.4% to USD 3.609 million due to increased foreign exchange losses [3][4][15]. Financial Performance Summary - Revenue projections for 2025-2027 are maintained at USD 856 million, USD 952 million, and USD 1.064 billion, reflecting year-on-year growth rates of 10.0%, 11.2%, and 11.7% respectively [8][15]. - Net profit attributable to shareholders is forecasted to be USD 40 million in 2025, USD 50 million in 2026, and USD 70 million in 2027, with corresponding growth rates of 102.4%, 23.5%, and 25.6% [8][15]. - The gross profit margin is projected to be around 66.3% in 2025, with net profit margins of 5.2%, 5.7%, and 6.4% for 2025, 2026, and 2027 respectively [8][15]. Operational Insights - The company’s restaurant operations generated USD 200 million in revenue for 3Q25, a 5.1% increase year-on-year, driven by network expansion and enhanced brand influence [4][5]. - The takeaway business saw significant growth, with revenue increasing by 69.2% to USD 4.4 million, attributed to product optimization and strategic marketing collaborations [4][5]. - The average table turnover rate improved to 3.9 times per day, reflecting the effectiveness of the company's customer and employee incentive strategies [5][6]. Market Position and Valuation - The target price is set at HKD 18.4, corresponding to a market capitalization of HKD 11.98 billion, based on a price-to-sales (P/S) ratio of 1.8 [2][15]. - The company’s current market capitalization is approximately HKD 9.25 billion, with a share price of HKD 14.22 as of November 27, 2025 [2][15].

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [2][51]. Core Insights - The company is positioned as a leading player in the express delivery industry, with a strong focus on scale and operational efficiency. It has implemented key strategies such as inter-provincial transportation, paid delivery fees, and shareholding reforms to enhance its competitive edge [9][13]. - The company has maintained a robust market share, with a 19.4% market share as of Q3 2025, reflecting a slight increase from 19.2% in H1 2025. The company has achieved a compound annual growth rate (CAGR) of 22.9% in net profit from 2021 to 2024 [9][16]. - The report forecasts significant revenue growth, projecting revenues of 48.87 billion yuan, 55.13 billion yuan, and 61.18 billion yuan for 2025, 2026, and 2027, respectively, alongside net profits of 9.69 billion yuan, 11.11 billion yuan, and 12.23 billion yuan for the same years [51]. Summary by Sections Company Overview - The company is recognized as a leading franchise express delivery service provider, achieving steady growth through strategic initiatives that have allowed it to outperform competitors [10][13]. - Key decisions such as the introduction of inter-provincial transportation and paid delivery fees have been pivotal in establishing the company as a market leader since 2016 [9][13]. Market Position and Performance - The company has a leading market share in the express delivery sector, with a 2025Q3 market share of 19.4%, up from 19.2% in H1 2025. The CAGR for express delivery volume from 2013 to 2024 was 37.0% [9][16]. - The company has demonstrated resilience in revenue growth, achieving a total revenue of 34.59 billion yuan in Q1-Q3 2025, reflecting a year-on-year growth of 10.3% [18]. Financial Projections - The report provides detailed financial forecasts, estimating revenues of 48.87 billion yuan, 55.13 billion yuan, and 61.18 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits of 9.69 billion yuan, 11.11 billion yuan, and 12.23 billion yuan [51][50]. Competitive Advantages - The company benefits from significant scale effects and a comprehensive cost-reduction strategy, which positions it favorably against competitors. The report highlights the company's ability to maintain a lower per-package cost compared to peers, with a projected cost of 0.60 yuan per package in Q3 2025 [30][45]. - The company's focus on service quality and operational efficiency has allowed it to achieve higher average delivery prices compared to competitors, with an average terminal price of 2.43 yuan in November 2023 [41][44]. Investment Recommendations - The report emphasizes the company's strong management and operational capabilities, projecting continued market share expansion and profitability in the long term. The anticipated price-to-earnings (PE) ratios for 2025, 2026, and 2027 are 12.26, 10.69, and 9.71, respectively [51][52].

Investment Rating - The report maintains a NEUTRAL rating for Li Auto with a target price of HK$81.34, reflecting a current price of HK$71.70 [2][6]. Core Insights - The one-off recall has disrupted quarterly earnings, but there is potential for a rapid recovery in Q4. The company reported a revenue of RMB 27.4 billion for Q3 2025, down 36% year-on-year and 10% quarter-on-quarter, with vehicle sales contributing RMB 25.9 billion [3][10]. - Li Auto is focusing on the 2026 facelifted L series as a growth driver, aiming to reclaim its leadership in the extended-range electric vehicle (EREV) segment. The company has started deliveries of the i6/i8 battery electric vehicle (BEV) models, enhancing its market presence [4][11]. - An organizational restructuring has been implemented to enhance decision-making speed and operational resilience, shifting back to a startup-style management approach [5][12]. Financial Summary - Revenue projections for 2025, 2026, and 2027 have been adjusted to RMB 111.6 billion, RMB 122.0 billion, and RMB 136.8 billion, respectively, reflecting a decrease of 14%, 28%, and 33% [6][13]. - The report indicates a non-GAAP net loss of RMB 360 million for Q3 2025, but underlying profitability is expected to return in Q4 2025 [3][10]. - The gross margin for Q3 was reported at 16.3%, with an underlying margin of 20.4% when excluding the recall impact [3][10].

Investment Rating - The investment rating for Alibaba-W (9988.HK) is "Buy" (maintained) [1] Core Views - The report highlights strong growth in cloud business and steady progress in domestic e-commerce commercialization, while also noting ongoing investments in instant retail [9] - The company reported a revenue of 247.8 billion yuan for FY2026Q2, reflecting a year-over-year increase of 5% and a quarter-over-quarter increase of 0.1% [10][11] - The adjusted EBITDA for the same period was 173 billion yuan, down 64% year-over-year [10][11] Summary by Sections Recent Performance - For FY2026Q2, Alibaba achieved a revenue of 247.8 billion yuan, with a net profit of 206 billion yuan, representing a year-over-year decline of 53% [10][11] - The company repurchased 17 million shares for a total of 253 million USD, with a remaining buyback capacity of 19.1 billion USD [10] Business Segments - **E-commerce**: The Chinese e-commerce group reported a revenue of 132.6 billion yuan, up 16% year-over-year, driven by a 10% increase in customer management revenue [12][32] - **Cloud Business**: The cloud segment saw a revenue increase of 34% to 39.8 billion yuan, with external cloud revenue growing by 29% [36] - **International Digital Commerce**: This segment achieved a revenue of 34.8 billion yuan, up 10% year-over-year, primarily due to improved operational efficiency [35] Financial Projections - Revenue projections for FY2026-2028 are set at 1,041.8 billion yuan, 1,160.5 billion yuan, and 1,282.1 billion yuan respectively, with corresponding net profits of 125.1 billion yuan, 149.3 billion yuan, and 184.5 billion yuan [9][37] - The target market capitalization for FY2027 is estimated at 3,345.5 billion yuan, with a target price of 175 yuan per share [9][38]

Investment Rating - The report assigns a "Buy" rating to the company, with a target price raised to HKD 39.50, indicating a potential upside of 25.1% from the current price of HKD 31.58 [2][11]. Core Insights - The report highlights the rapid advancement of the overseas development of SSGJ-707, with Pfizer planning to initiate at least seven clinical trials soon, including two global Phase III trials targeting first-line squamous and non-squamous non-small cell lung cancer (NSCLC) and metastatic colorectal cancer [6]. - The company plans to spin off its consumer pharmaceutical business, Mandi International, to focus on its core prescription and innovative drug sectors, which is expected to generate short-term investment returns and support the development of innovative products [6]. - The report expresses increased confidence in the global development potential of SSGJ-707 due to strong clinical data and support from partners, leading to an adjustment in long-term milestone payment forecasts [6]. Financial Overview - Revenue projections for the company are as follows: RMB 7,816 million in 2023, RMB 9,108 million in 2024, and a significant increase to RMB 17,470 million in 2025, followed by a decline to RMB 12,821 million in 2026 and RMB 12,018 million in 2027, reflecting a growth rate of 91.8% in 2025 [5][14]. - Net profit is expected to rise sharply to RMB 8,057 million in 2025, with a corresponding earnings per share (EPS) of RMB 3.34, before declining in subsequent years [5][14]. - The company’s market capitalization is reported at approximately HKD 75.55 billion, with a year-to-date price change of 419.41% [4]. Valuation Model - The discounted cash flow (DCF) model estimates the equity value at approximately RMB 87.35 billion, translating to a per-share value of HKD 39.50, based on a weighted average cost of capital (WACC) of 9.4% [10][11].